DyStar Becomes a Wholly-Owned Subsidiary of Zhejiang Longsheng Group, Ending Longstanding Shareholder Disputes with a $5 Billion Deal
On January 5, 2026, DyStar Group, a century-old specialty chemicals and dyes manufacturer, officially announced that it has become a wholly-owned subsidiary of Zhejiang Longsheng Group Co., Ltd. (“Zhejiang Longsheng”). This change in controlling ownership marks a key step forward in resolving long-standing disputes, achieving strategic synergy, and advancing global business expansion.
I. Transaction Background and Acquisition Overview
On May 29, 2025, Zhejiang Longsheng’s board of directors approved a proposal to acquire the remaining minority interests in DyStar. The plan involved a combination of a share buyback and equity purchase to acquire the remaining 37.57% of DyStar shares, thereby gaining full control of the company. According to the transaction agreement, the total price for this equity acquisition was approximately USD 702 million (approximately RMB 5.017 billion).
The strategic purpose of this acquisition is to fully resolve the long-standing litigation between Zhejiang Longsheng and India’s KIRI Industries Limited (“KIRI”) regarding DyStar’s shares, while supporting Zhejiang Longsheng’s long-term goal of becoming a leading global specialty chemicals company.
The transaction was completed on December 30, 2025, with subsequent registration of the shareholding changes at relevant authorities in Singapore. As of December 31, 2025, Zhejiang Longsheng officially gained full ownership of DyStar.
II. Transaction Structure and Shareholding Changes
The acquisition was implemented in two parts:
DyStar Share Buyback – DyStar repurchased 20% of shares through designated accounts.
Acquisition of Minority Interests – A wholly-owned subsidiary of Zhejiang Longsheng paid for the remaining 17.57% of shares.
These two components together accounted for the full equity transfer. After completion, Zhejiang Longsheng indirectly holds 100% of DyStar’s shares through three wholly-owned subsidiaries.
The post-transaction shareholding structure of DyStar is as follows:
| Shareholder | Shareholding (%) |
|---|---|
| Shengda International Capital Ltd. | 78.04% |
| Shengde International Capital Ltd. | 21.96% |
| Huaseng Ltd. | Minimal (~0.00002%) |
III. Dispute Resolution and Business Impact
The completion of this acquisition marks the formal end of the long-standing litigation between Zhejiang Longsheng and KIRI over DyStar’s shares. Following the transaction, the two directors appointed by KIRI resigned, streamlining the corporate governance structure and paving the way for unified management and coordinated development.
As of December 30, 2025, DyStar officially became a wholly-owned subsidiary of Zhejiang Longsheng. Going forward, all net profits generated by DyStar will belong to the parent company’s shareholders, which is expected to significantly enhance Zhejiang Longsheng’s future net profit attributable to shareholders.
DyStar stated that officially becoming a wholly-owned subsidiary marks the beginning of a “new phase of stable governance, clear strategic direction, and long-term growth.”
2026-10-11
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
DyStar to Discontinue Hilton Davis Operations and Partially Consolidate Reedsville Site
-
Westlake Acquires ACI's Composites Business to Expand Global Footprint
-
BASF Moves to Sell 4,400 Employee Homes—Union Fury Reveals the Survival Math of a Chemical Giant
-
BASF Battles Market Turmoil as Profits Slide
-
IMCD Opens Beauty and Personal Care Lab in California
-
The Most Striking Thing in BASF’s 2025 Results Isn’t Profit — It’s “Cutting Weight” and “Stopping the Bleeding” at the Same Time
-
$12 Billion Merger! A New North American Chemical Giant Is About to Be Born
-
“Shutdown Equals Price Hike”: TDI Market Enters a New Era of “Scarcity Games”
-
Merck and Eisai Halt Late-Stage Trial for Liver Cancer Therapy
-
China National Salt Industry Corporation Advances 10,000 t/y Sodium Metal Expansion Project, Industry Leader Invests Nearly RMB 100 Million
Recommend Reading
-
Pfizer Sues Metsera and Novo Nordisk Over Rival Obesity Drug Strategy
-
Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera
-
Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook
-
Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera
-
Türkiye Advances $3 Billion Petrochemical Cluster Targeting 17% of Domestic Polypropylene Demand
-
This week, the Aniline market in China showed a strong increase (1.5-1.9)
-
Business Society’s Market Outlook for Ethanol on August 26, 2026: Volatile Consolidation
-
Business Society’s BDO Market Outlook on August 25, 2026: Clearly Upward Trend
-
Escalation of Middle East Conflict Drives Significant Increase in China's Gasoline and Diesel Prices
-
MTBE Market Prices Fluctuate and Decline